BFEC
GERM

Benjamin F. Edwards & Company’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Benjamin F. Edwards & Company’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$80K – 1785
2021
Q2 		$80K Hold
2,000
– – ﹤0.01% 903
2021
Q1 		$71K Hold
2,000
– – ﹤0.01% 923
2020
Q4 		$62K Buy
+2,000
New +$60.9K ﹤0.01% 912

Other funds holding GERM

LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
G
Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return

Benjamin F. Edwards & Company's GERM Position: Q3 2021 in Review

Benjamin F. Edwards & Company sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2021, closing a stake of 2,000 shares — an estimated $80K sold.

Benjamin F. Edwards & Company first reported a position in GERM in Q4 2020 and held it in 3 quarters. The position peaked at $80K in Q2 2021. 24 funds tracked by Wall St. Rank hold GERM as of Q3 2021.

  • Benjamin F. Edwards & Company reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2021 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 2,000 Amplify Treatments, Testing and Advancements ETF shares in Q3 2021, an estimated $80K.
  • Benjamin F. Edwards & Company first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2020 and held it in 3 quarters.
  • Benjamin F. Edwards & Company's Amplify Treatments, Testing and Advancements ETF position peaked at $80K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2021.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2021, filed 2 Nov 2021.